FreeTheAI

Establishment Labs Gains as Stifel Starts Coverage With Buy Rating

BullishMedium impact
ESTA$61.65 6.51%

Establishment Labs Holdings, Inc. (NASDAQ:ESTA) rose 5.68% to $61.17 on Thursday after Stifel initiated coverage of the breast implant maker with a Buy rating and an $84 price target. The analyst cited stronger-than-expected growth prospects for the breast augmentation market.

The view was based in part on a survey of 66 U.S. plastic surgeons. Seventy-four percent expected the market to grow over the next three years, while 25% expected no change and 2% anticipated a decline.

Survey respondents also expected Establishment Labs to gain market share over the next two years. The company’s minimally invasive product portfolio was seen as capable of expanding the overall market and supporting adoption among more surgeons.

Stifel noted that the stock trades at less than six times estimated 2027 sales, about a 1.5-times premium to its three-year average. The analyst said potential conservatism in market and Stifel revenue estimates, along with improved profitability, could provide additional upside. Investors will watch the company’s market-share gains, product adoption and revenue performance.

Key points

  • Stifel initiated coverage of Establishment Labs with a Buy rating and an $84 price target.
  • Establishment Labs shares rose 5.68% to $61.17 on Thursday.
  • In a survey, 74% of 66 U.S. plastic surgeons expected breast augmentation market growth over three years.
  • Survey respondents expected Establishment Labs to gain market share over the next two years.
  • Stifel said the company’s valuation and profitability profile could support additional upside.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Establishment Labs stock rise on October 15, 2026?

Shares rose after Stifel began coverage with a Buy rating and an $84 target, citing growth prospects in the breast augmentation market.

What is Stifel’s price target for Establishment Labs?

Stifel set an $84 price target for Establishment Labs, whose shares were trading at $61.17 after rising 5.68%.

What are plastic surgeons expecting from the breast augmentation market?

In a survey of 66 U.S. plastic surgeons, 74% expected the market to grow over the next three years.